Heart Pump Device Market, By Type (Implantable Heart Pump Devices and Extracorporeal Heart Pump Devices), By Product (Intra-aortic Balloon Pumps, Ventricular Assist Devices (RVAD, LVAD, pVAD, BiVAD), and TAH (Total Artificial Heart)), By Therapy (Destination Therapy, Bridge to Transplant, and Others), By End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), and By Region - Trends, Analysis and Forecast till 2034

Heart pump device sales are expected to reach US$ 17.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 17.80% from its estimated US$ 3.9 billion in 2024.

A new age in cardiovascular care has been brought about by the widespread success of mechanical circulatory support systems, such as heart pump devices. Today, severe heart failure can be treated with a variety of implanted devices. For people with weak hearts and erratic blood flow, surgically implanted heart pump devices provide temporary heart support.

The target market is anticipated to increase as a result of technological advancements and the existence of significant important players in the heart pump device manufacturing process. Long-term heart pump device approval has emerged as a key driver of target market expansion. For example, HeartMate III and HeartWare HVAD were authorized by the FDA (Food and Drug Administration) in 2017 and 2018 for use in patients with cardiovascular illnesses who require long-term mechanical assistance.